전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,016 programs
CGTLimited DatastaleHyungwoo ChoPhase 2

Anbal-cel (Anbal-cel)

Primary CNS Lymphoma (PCNSL); Diffuse Large B Cell Lymphoma (DLBCL) · Primary CNS Lymphoma (PCNSL)

#PrimaryCNSLymphomaPCNSL#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleHenan Cancer HospitalPhase 2

durvalumab (Imfinzi, Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer)

SCLC, Extensive Stage · SCLC, Extensive Stage

#SCLCExtensiveStage#Antibody#Phase2#monoclonal-antibody#SCLC+2
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B-cell maturation antigen (BCMA, Anti-B-cell maturation antigen, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells)

Myeloma, Plasma-Cell; Myeloma-Multiple · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
AntibodyLimited DatastaleGlaxoSmithKlinePhase 2

Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody, Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab))

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
CGTLimited DatastaleShenzhen Institute for Innovati…Phase 1

Anti-CD19-CAR transduced T cells (Anti-CD19-CAR transduced T cells)

Chronic Lymphocytic Leukemia; Acute Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSumithira VasuPhase 1

Anti-CD19/CD20/CD22 CAR T-Cells (Anti-CD19/CD20/CD22 CAR T-Cells)

Recurrent Acute Lymphoblastic Leukemia; Recurrent B Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

Anti-CTLA-4/PD-1 expressing MUC1-CAR-T (Anti-CTLA-4/PD-1 expressing MUC1-CAR-T)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleBenaroya Research InstitutePhase 2

Panitumumab or Cetuximab (Anti-EGFR, Anti-EGFR (Panitumumab or Cetuximab))

Colorectal Cancer; Cholangiocarcinoma · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#ColorectalCancer+2
Trials 1Status Active
CGTLimited Datastale920th Hospital of Joint Logisti…Phase 2

Anti-GPRC5D CAR-T cells infusion (Anti-GPRC5D CAR-T cells infusion)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · GPRC5D

#GPRC5D#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

Anti-PD-1 Antibody Plus Chidamide and Rituximab (Anti-PD-1 Antibody Plus Chidamide and Rituximab)

Relapsed or Refractory DLBCL · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryDLBCL+1
Trials 1Status Active
CGTLimited DatastaleJiangsu Topcel-KH Pharmaceutica…Phase 1

Anti-PD1 armored CD19 CAR-T cells (Anti-PD1 armored CD19 CAR-T cells)

Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBristol-Myers SquibbPhase 1

Anti-Signaling lymphocytic activation molecule F7 (SLAMF7, Anti-Signaling lymphocytic activation molecule F7, Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · Myeloma-Multiple

#Myeloma-Multiple#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleJanssenApproved

Infusion (Anti-TNF: Infliximab, Anti-TNF: Infliximab (Infusion))

Crohn's Disease; Inflammatory Bowel Disease · Crohn's Disease

#CrohnsDisease#Antibody#Approved#monoclonal-antibody#InflammatoryBowelDisease+1
Trials 1Status Active
AntibodyLimited DatastaleAbbVieApproved

Subcutaneus (Anti-TNF:Adalimumab, Anti-TNF:Adalimumab (Subcutaneus))

Crohn's Disease; Inflammatory Bowel Disease · Crohn's Disease

#CrohnsDisease#Antibody#Approved#monoclonal-antibody#InflammatoryBowelDisease+1
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-Tumor Necrosis Factor (TNF, Anti-Tumor Necrosis Factor, Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, Large-Cell, Anaplastic; Enteropathy-Associated T-Cell Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

Metastatic Cancer; Metastatic Melanoma · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

Antigen-specific CAR T, CTL and DCvac to treat melanoma. (Antigen-specific CAR T, CTL and DCvac to treat melanoma.)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
ADCLimited DatastaleCentral South UniversityPreclinical

Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate (Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate)

Sepsis (SMQ); Opportunistic Infections · Sepsis (SMQ)

#SepsisSMQ#ADC#Preclinical#antibody-drug-conjugate#OpportunisticInfections+1
Trials 1Status Active
AntibodyLimited DatastaleInstitut BergoniéPhase 2

durvalumab (Imfinzi, Association of lurbinectedin and durvalumab)

Small Cell Lung Cancer; Platinum-Sensitive Lung Small Cell Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Platinum-SensitiveLungSmallCellC+1
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ])

Lymphoma, Follicular · Lymphoma, Follicular

#LymphomaFollicular#Antibody#Phase2#monoclonal-antibody#Lymphoma+2
Trials 1Status Active

21 / 51 pages

← PreviousNext →